Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma

By afschroeder • March 7, 2026

Colevas AD, Chin V, Park JJ, Adkins D, Phan M, Fang B, Forget F, Amorim J, Misiukiewicz K, Costa DA, Rainey N, Even C, Wong DJ, Kerrigan K, Zhang Y, Dong M, Rong R, Caldwell K, Leung C, Dinis J. Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma. ESMO Open. 2026 Mar 4;11(3):106085. doi: 10.1016/j.esmoop.2026.106085. Epub ahead of print. PMID: 41785669.

Tags: docetaxel, Hematology/Oncology, magrolimab, metastatic head and neck squamous-cell carcinoma, pembrolizumab, Publications, zimberelimab

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors[...]

The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer

Leonhardt CS, Adham M, Bazarbashi S, Ben-Aharon I, Beets-Tan RGH, Boggi U, Brunner TB, Cellini F, Chiti A, Daamen L, De Bari B, De Dosso[...]

Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study

Yu HA, Tang KH, Markovets AA, Hartmaier R, Smith PE, Cho BC, De Langen AJ, Goldberg SB, Goldman JW, Le X, Iwama E, Cosaert J,[...]